Skip to main content

Advertisement

SpringerLink
Log in

Distinct Cytokine and Chemokine Expression in Plasma and Calpeptin-Treated PBMCs of a Relapsing-Remitting Multiple Sclerosis Patient: A Case Report

  • Short Communication
  • Published:
Neurochemical Research Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The cytokine/chemokine expression signature of a 60-year-old African American male with relapsing-remitting multiple sclerosis (RRMS) was analyzed using patient blood samples obtained from two separate visits to the clinic. Thirty-six different cytokines, chemokines, and growth factors were detected in the plasma of the RRMS patient using a multiplexed bead-based immunoassay. Results indicated that at least ten of these factors with a concentration of > 100 pg/mL are identified as pro-inflammatory. Calpain inhibition led to an anti-inflammatory effect, as indicated by a decrease in expression of pro-inflammatory cytokines/chemokines such as GM-CSF, IFNγ, and IL-17A, and a relative increase in two of the anti-inflammatory cytokines (IL-13 and IL-4) in the peripheral blood mononuclear cells activated with anti-CD3/CD28. Overall, these results suggest that the unique cytokine/chemokine pattern observed in the plasma of the RRMS patient can be used as a prognostic marker and calpain inhibition may be used as a novel therapeutic strategy for treating excessive inflammatory response specific to RRMS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Amedei A, Prisco D, D’Elios MM (2012) Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci 13(10):13438–13460

    Article  CAS  Google Scholar 

  2. Tullman MJ (2013) Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Managed Care 19(2 Suppl):S15–S20

    Google Scholar 

  3. Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1–5

    Article  Google Scholar 

  4. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286

    Article  Google Scholar 

  5. Trager N, Butler JT, Haque A, Ray SK, Beeson C, Banik NL (2013) The involvement of calpain in CD4(+) T helper cell bias in multple sclerosis. J Clin Cell Immunol 4(4):1000153

    Article  Google Scholar 

  6. Dendrou CA, Fugger L (2017) Immunomodulation in multiple sclerosis: promises and pitfalls. Curr Opin Immunol 49:37–43

    Article  CAS  Google Scholar 

  7. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545–558

    Article  CAS  Google Scholar 

  8. Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J et al (2017) Multiple sclerosis: immunopathology and treatment update. Brain Sci 7(7):78

    Article  Google Scholar 

  9. Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255(10):1449–1463

    Article  CAS  Google Scholar 

  10. Ellwardt E, Zipp F (2014) Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp Neurol 262(Pt A):8–17

    Article  CAS  Google Scholar 

  11. Schaecher KE, Shields DC, Banik NL (2001) Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain. Neurochem Res 26(6):731–737

    Article  CAS  Google Scholar 

  12. Shields DC, Schaecher KE, Saido TC, Banik NL (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 96(20):11486–11491

    Article  CAS  Google Scholar 

  13. Shields DC, Banik NL (1999) Pathophysiological role of calpain in experimental demyelination. J Neurosci Res 55(5):533–541

    Article  CAS  Google Scholar 

  14. Guyton MK, Das A, Samantaray S, Wallace GC, Butler JT, Ray SK et al (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88(11):2398–2408

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Podbielska M, Das A, Smith AW, Chauhan A, Ray SK, Inoue J et al (2016) Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation. J Neurochem 139(3):440–455

    Article  CAS  Google Scholar 

  16. Smith AW, Doonan BP, Tyor WR, Abou-Fayssal N, Haque A, Banik NL (2011) Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol 232(1–2):179–185

    Article  CAS  Google Scholar 

  17. Sullivan KE, Cutilli J, Piliero LM, Ghavimi-Alagha D, Starr SE, Campbell DE et al (2000) Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 7(6):920–924

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Verhoef CM, Van Roon JA, Vianen ME, Glaudemans CA, Lafeber FP, Bijlsma JW (1999) Lymphocyte stimulation by CD3-CD28 enables detection of low T cell interferon-gamma and interleukin-4 production in rheumatoid arthritis. Scand J Immunol 50(4):427–432

    Article  CAS  Google Scholar 

  19. Mori F, Rossi S, Piccinin S, Motta C, Mango D, Kusayanagi H et al (2013) Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. J Neurosci 33(49):19112–19119

    Article  CAS  Google Scholar 

  20. Stampanoni Bassi M, Iezzi E, Marfia GA, Simonelli I, Musella A, Mandolesi G et al (2018) Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. J Neuroinflamm 15(1):108

    Article  Google Scholar 

  21. Mori F, Nistico R, Nicoletti CG, Zagaglia S, Mandolesi G, Piccinin S et al (2016) RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Mult Scler (Basingstoke, England). 22(11):1405–1412

    Article  CAS  Google Scholar 

  22. Filipovic R, Jakovcevski I, Zecevic N (2003) GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci 25(2–4):279–290

    Article  CAS  Google Scholar 

  23. Glabinski AR, Tuohy VK, Ransohoff RM (1998) Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 5(3–4):166–171

    Article  CAS  Google Scholar 

  24. Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S (2017) Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. J Neuroimmunol 305:102–107

    Article  CAS  Google Scholar 

  25. Masuda H, Mori M, Umehara K, Furihata T, Uchida T, Uzawa A et al (2018) Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. J Neuroimmunol 316:117–120

    Article  CAS  Google Scholar 

  26. Shields DC, Tyor WR, Deibler GE, Banik NL (1998) Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. Brain Res 784(1–2):299–304

    Article  CAS  Google Scholar 

  27. Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL (1998) Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 95(10):5768–5772

    Article  CAS  Google Scholar 

  28. Shields DC, Banik NL (1998) Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. Brain Res 794(1):68–74

    Article  CAS  Google Scholar 

  29. Schaecher K, Rocchini A, Dinkins J, Matzelle DD, Banik NL (2002) Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J Neuroimmunol 129(1–2):1–9

    Article  CAS  Google Scholar 

  30. Shields DC, Schaecher KE, Goust JM, Banik NL (1999) Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. J Neuroimmunol 99(1):1–12

    Article  CAS  Google Scholar 

  31. Das A, Guyton MK, Matzelle DD, Ray SK, Banik NL (2008) Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. J Neurosci Res 86(13):2992–3001

    Article  CAS  Google Scholar 

  32. Imam SA, Guyton MK, Haque A, Vandenbark A, Tyor WR, Ray SK et al (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190(1–2):139–145

    Article  CAS  Google Scholar 

  33. Trager N, Smith A, Wallace G IV, Azuma M, Inoue J, Beeson C et al (2014) Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. J Neurochem 130(2):268–279

    Article  CAS  Google Scholar 

  34. Samantaray S, Knaryan VH, Shields DC, Cox AA, Haque A, Banik NL (2015) Inhibition of calpain activation protects MPTP-induced nigral and spinal cord neurodegeneration, reduces inflammation, and improves gait dynamics in mice. Mol Neurobiol 52(2):1054–1066

    Article  CAS  Google Scholar 

  35. Samantaray S, Knaryan VH, Le Gal C, Ray SK, Banik NL (2011) Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone. Neuroscience 192:263–274

    Article  CAS  Google Scholar 

  36. Smith AW, Rohrer B, Wheless L, Samantaray S, Ray SK, Inoue J et al (2016) Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis. J Neurochem 139(2):270–284

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by funding Veterans Administration (1I01BX002349-01); Department of Neurosurgery, MUSC, and MUSC-CTSA program; and the South Carolina State Spinal Cord Research Fund (SCIRF-2015P-01, SCIRF-2015P-04, SCIRF-2015-I-01, SCIRF-2016 I-03). Contents do not necessarily represent the policy of the SCIRF and do not imply endorsement by the funding agency.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St. MSC606 Suite 301, Charleston, SC, 29425, USA

    Raghavendar Chandran, Mollie Capone, Denise Matzelle & Naren L. Banik

  2. Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

    Mollie Capone, Rachel Polcyn, Azizul Haque & Naren L. Banik

  3. Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA

    Denise Matzelle, Elizabeth Kau & Naren L. Banik

Authors
  1. Raghavendar Chandran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mollie Capone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denise Matzelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rachel Polcyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elizabeth Kau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Azizul Haque
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naren L. Banik
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RC wrote the manuscript and drew the Figures and Tables. MC performed the experiments. DM coordinated patient study, collected samples, and edited the manuscript. AH conceived and designed the experiments and the manuscript. NB conceived and designed the manuscript. AH and NB also edited the manuscript. EK provided patient samples and case history. All authors reviewed and approved the final version of the manuscript.

Corresponding authors

Correspondence to Azizul Haque or Naren L. Banik.

Ethics declarations

Conflict of interest

The authors have no financial conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandran, R., Capone, M., Matzelle, D. et al. Distinct Cytokine and Chemokine Expression in Plasma and Calpeptin-Treated PBMCs of a Relapsing-Remitting Multiple Sclerosis Patient: A Case Report. Neurochem Res 43, 2224–2231 (2018). https://doi.org/10.1007/s11064-018-2655-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-018-2655-z

Keywords

Search

Navigation